Cancer cells can treat tumors

Cancer cells can treat tumors.


New inquiry suggests that many cancer cells are equipped with a amicable of suicide pill: a protein on their surfaces that gives them the proficiency to fire an "eat me" beckon to immune cells. The dispute now, the researchers say, is to appear out how to coax cancer cells into emitting the special rather than a dangerous "don't eat me" signal tumblr compare penis. A con published online Dec 22 2010 in Science Translational Medicine reports that the cells stir out the enticing "eat me" whistle by displaying the protein calreticulin.



But another molecule, called CD47, allows most cancer cells to shun assassination by sending the different signal: "Don't breakfast me". In earlier research, Stanford University School of Medicine scientists found that an antibody that blocks CD47 - turning off the singular - could assistant feud cancer, but mysteries remained. "Many routine cells in the body have CD47, and yet those cells are not sham by the anti-CD47 antibody," Mark Chao, a Stanford mark follower and the study's lead author, said in a university copy release.



And "At that time, we knew that anti-CD47 antibody healing selectively killed only cancer cells without being toxic to most typical cells, although we didn't certain why". Now, the redone research has shown that calreticulin exists in a miscellany of cancers, including some types of leukemia, non-Hodgkin's lymphoma and bladder, acumen and ovarian cancers.



So "This experimentation demonstrates that the defence that blocking the CD47 'don't eat me' unique works to kill cancer is that leukemias, lymphomas and many swarming tumors also display a calreticulin 'eat me' signal," Dr Irving Weissman, the man of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. "The study also shows that most natural cubicle populations don't unveil calreticulin and are, therefore, not depleted when we imperil them to a blocking anti-CD47 antibody".



The next progression is to be aware how calreticulin works. "We want to grasp how it contributes to the disease process and what is occurrence in the cell that causes the protein to move to the chamber surface," Dr Ravindra Majeti, an second professor of hematology and study co-principal investigator, said in the release iphone helsinki. "Any of these mechanisms furnish concealed new ways to treat the malady by interfering with those processes," Majeti said.